Jones Mitchell Lawrence 4

What Happened

• Jones Mitchell Lawrence, Chief Medical Officer of Palisade Bio (PALI), had 131,167 restricted stock units (RSUs) settle into common shares on July 6, 2026. Following that settlement, he sold 51,880 shares in the open market on July 7, 2026 at a weighted average price of $2.05, generating proceeds of about $106,536. The sale was disclosed as a tax-withholding sale related to the RSU settlement.
• Net result: 131,167 shares were issued on vesting and, after the sale of 51,880 shares to cover taxes, the reporting person retained a net increase of 79,287 shares from this vesting event. The open-market sale prices ranged from $2.045 to $2.06.

Key Details

• Transaction dates: RSU settlement (conversion) on 2026-07-06; open-market sale on 2026-07-07.
• Sale price: weighted average $2.05 (range $2.045–$2.06); proceeds ≈ $106,536.
• Shares acquired via settlement: 131,167 RSUs converted to 131,167 shares (F1, F5).
• Shares sold to cover taxes: 51,880 (F3). Net added shares from vesting after the sale: 79,287.
• Other holdings noted: filing references 1,459 shares from the company ESPP acquired May 20, 2026 (F2).
• Vesting schedule note: the RSUs vest 1/6 on July 6, 2026 and quarterly thereafter over 10 quarters, subject to continued service (F6).
• Filing: Form 4 filed 2026-07-08 reporting the July 6–7 transactions; this appears to be within the typical two-business-day Form 4 filing window.
• Derivative explanation: the RSU settlement is recorded as a conversion/exercise-type transaction (derivative code M) converting contingent RSUs into common shares.

Context

• This was primarily a settlement of vested RSUs with a partial open-market sale to satisfy tax withholding—routine compensation-related activity rather than a pure investment purchase or directional trade. The sale does not necessarily indicate a change in the insider’s view of the company.